Zarxio 15% Price Discount To Neupogen In US Tracks European Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz's discount to Amgen is not as deep as some expected, but is likely to increase over time.
You may also be interested in...
Adello’s Filgrastim Biosimilar Faces Infringement Lawsuit And Potential Regulatory Delay
US FDA user fee date for privately held company’s 351(k) application referencing Amgen’s Neupogen may have passed without word of a regulatory action; Amgen sued Adello in March alleging infringement of 17 patents covering the innovator product.
Adello’s Filgrastim Biosimilar Faces Infringement Lawsuit And Potential Regulatory Delay
US FDA user fee date for privately held company’s 351(k) application referencing Amgen’s Neupogen may have passed without word of a regulatory action; Amgen sued Adello in March alleging infringement of 17 patents covering the innovator product.
Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017
Zarxio and Basaglar will be the beneficiaries of the cost-cutting move, although how much it will help the follow-on products remains unclear.